THERAPEUTICSMD INC

TXMDNASDAQ

🏆 #4735 by market capEarnings Nov 17US Equity

$664.69▼ $0.47 (−0.07%)

Simulated price

🔔

Track TXMD

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 0.1%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$24M

Small Cap

📈Revenue Growth (YoY)

+71.6%

High Growth

📊Gross Margin

89.9%

High

💵FCF Margin

95.4%

Strong

⚖️P/S Ratio

7.4x

Fair

Otter Score

Weak

No chart data available for TXMD.

Trading Snapshot

Day Range: $656.35 – $669.74
52-Week Range: $0.99 – $2.95
Volume: $2.33B
Avg Volume: $2.66B
Shares Outstanding: 11.6M
Next Earnings: Dec 15, 2026

Fundamentals Snapshot

Annual Revenue: $3M
Last Q Revenue: $869,000
P/E Ratio: -111.2
P/S Ratio: 7.4x
EPS (TTM): $-0.02
Dividend Yield: 0.00%
Dilution (1yr): +0.3%

Why Investors Own TXMD

✓High-growth profile — revenue up +2.2% YoY with expanding US Equity exposure.
✓Healthy economics — 36% gross margin and 28% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

THERAPEUTICSMD INC

TXMD

Financial Trends

Revenue

$3M▲ +71.6% YoY

Gross Margin

100.0%▲ +0.0% YoY

Operating Income

−$4M▼ −13.0% YoY

Free Cash Flow

$2M▲ +231.1% YoY

Shares Outstanding

11.6M▲ +0.3% YoY

Net Cash

$1M▲ +$4M YoY

StockOtter · stockotter.space

About THERAPEUTICSMD INC

TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradiol and progesterone, used to alleviate moderate to severe vasomotor symptoms; and ANNOVERA, an innovative vaginal ring designed for contraception. In its developmental pipeline, TherapeuticsMD is advancing several preclinical candidates: TX-005HR, a transdermal cream containing only progesterone; TX-006HR, another transdermal cream formulated with both estradiol and progesterone; TX-007HR and TX-008HR, both experimental transdermal patches; and TX-009HR, an oral formulation of progesterone and estradiol. Beyond its core pharmaceutical offerings, the company produces and distributes both branded and generic prescription prenatal vitamins, notably under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 labels. Its prescription medications and prenatal vitamin lines reach consumers through established channels, including wholesale and retail pharmacy distributors. Established in 2008, TherapeuticsMD, Inc. maintains its corporate headquarters in Boca Raton, Florida.

🦦